Eng

Indian court summons Alibaba founder Jack Ma over fake news and censorship

KrASIA
更新於 2020年07月27日16:27 • 發布於 2020年07月27日08:27 • Wency Chen

Alibaba founder Jack Ma was summoned by an India court in Gurugram after a former employee claimed he was sacked by subsidiary UC Web for objecting to censorship and fake news on its apps. The summon comes as Chinese internet companies face mounting political pressure in India, Reuters reported first on July 26.

Pushpandra Singh Parmar, who was an associate director of UC Web and UC News from 2016 to 2017 according to his LinkedIn page, filed a case on July 20, alleging the company’s apps censored content unfriendly to China and hosted fake news.

The judge in Gurugram, a satellite city of India’s capital New Delhi, has already issued a summons for Alibaba, Jack Ma, and about a dozen individuals and company units, according to the Reuters report. The entities or their lawyers are required to appear in court on July 29 and submit written responses within 30 days.

廣告(請繼續閱讀本文)

In response, Wang Shuai, chairman of the marketing and public relations committee at Alibaba, confirmed the news on Sunday.

“UC India did get informed of this and is now handling the case by the process,” he said.

He also joked about the summon. “I’m not sure where Ma knows this or not,” he wrote on WeChat Moment.  “It’s very hard to find him after he retired.”

廣告(請繼續閱讀本文)

UC India said in a statement it had been “unwavering in its commitment to the Indian market and the welfare of its local employees, and its policies are in compliance with local laws. We are unable to comment on ongoing litigation,” Reuters wrote.

Alibaba declined to comment when asked byKrASIA.

In early June, UC News was reportedly close to a shutdown in India due to its monetization struggle, KrASIA wrote. UCWeb also operates UC Browser and short video app Vmate in India, but the India ban on Chinese apps issued about one month ago affected all the three apps, which have already been taken down from Indian app stores.

廣告(請繼續閱讀本文)
查看原始文章

更多 Eng 相關文章

Xinhua Commentary: Chinese economy progressing well in pursuit of 2024 targets
XINHUA
LG Innotek Shines on Global Stage with Automotive Lighting Innovations
PR Newswire (美通社)
Drones relay to complete power network inspections
XINHUA
Xinhua News | Arab League condemns U.S. veto on UN resolution demanding Gaza ceasefire
XINHUA
BingX Launches Spot Innovation Zone to Capture Opportunities in Bullish Markets
PR Newswire (美通社)
FedEx boosts Xiamen-U.S. cargo flight services
XINHUA
Sungrow Strengthens Australian Market Presence with 1.7GWh of C&I Energy Storage Partnerships with Raystech and Solar Juice
PR Newswire (美通社)
Proposed U.S. tariffs risk fueling inflation, slowing economic growth: economists
XINHUA
HKFDA’s Virtuose puts Hong Kong at the forefront of fashion through a stunning couture showcase
Tatler Hong Kong
CCTV+: Embarking on a Renewed Dialogue at Liangzhu Between Global Civilizations--The 'Liangzhu: A Dialogue across World Civilizations' Promotional Video and Documentary to Premier
PR Newswire (美通社)
Hanwha Power Systems signs MOU with TC Energy to accelerate commercialization of sCO2 power generation
PR Newswire (美通社)
Global Times: Neo-Chinese cuisine: How China is reimagining its food heritage
PR Newswire (美通社)
Cambodia targets 70 pct clean energy by 2030: minister
XINHUA
Turfan's Real-Time Power Response System Boosts Regional Tourism
PR Newswire (美通社)
The Global AI Defense Challenge 2024 Announces Winners Across Two Competition Tracks
PR Newswire (美通社)
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
PR Newswire (美通社)
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
PR Newswire (美通社)
Update: China has half of top 20 science cities: Nature Index
XINHUA
Tourism revenue hits new high at Horgos port in Xinjiang
XINHUA
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
PR Newswire (美通社)